Optimel Manuka Dry Eye Drops

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of burning and irritation due to dryness of the eye. It serves as a protectant against further irritation and is effective in alleviating symptoms associated with dry eyes.

There are no known teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to ensure proper hand hygiene prior to administration. The recommended dosage for the affected eye is to instill 1 drop into the inner corner, with a maximum frequency of 3 times daily.

For patients under 16 years of age, it is essential to consult a physician before proceeding with treatment.

Contraindications

Use is contraindicated in patients with a history of hypersensitivity or sensitivity to honey or benzoate preservatives without prior medical consultation.

The product should not be used if the solution exhibits any color change or becomes cloudy, as this may indicate instability. Additionally, do not use if the packaging is damaged, as this could compromise the integrity of the product. Serious medical conditions should be managed under the supervision of a healthcare professional.

Warnings and Precautions

For external use only.

Healthcare professionals should advise patients to exercise caution when using this product. It is contraindicated in individuals with a history of hypersensitivity or sensitivity to honey or benzoate preservatives unless medical advice has been sought. The product should not be used if the solution exhibits any changes in color or becomes cloudy, nor should it be used if the packaging is damaged. Serious medical conditions necessitate management under the supervision of a healthcare provider.

Patients should be instructed to discontinue use and consult a physician if they experience any of the following: eye pain, changes in vision, persistent redness, or irritation of the eye. Additionally, if the condition worsens, medical advice should be sought promptly.

In the event of accidental ingestion, it is imperative to seek emergency medical assistance or contact a Poison Control Center immediately.

Side Effects

For external use only. Patients should discontinue use and consult a doctor if they experience any of the following: eye pain, changes in vision, continued redness or irritation of the eye, or if their condition worsens.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Optimel Manuka Dry Eye Drops (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 16 years of age should consult a healthcare professional before use. It is important for healthcare providers to evaluate the appropriateness of treatment in this age group, considering potential differences in efficacy and safety profiles compared to older populations.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The available prescribing information does not provide specific data regarding the use of this product during pregnancy. There are no contraindications noted for use in pregnant patients, nor are there any associated risks to the fetus identified in the available literature. Additionally, no dosage modifications or special precautions for use during pregnancy are mentioned. Healthcare professionals should consider the lack of data when prescribing this product to women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants during the use of this product in lactation.

Renal Impairment

Patients with renal impairment have no specific information regarding dosage adjustments, special monitoring, or safety considerations provided in the insert text. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of data necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, increased severity of known side effects, unusual behavioral changes, or any other atypical clinical manifestations.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on the management of overdose cases.

In summary, while specific overdosage information is not available, healthcare professionals should exercise caution, remain observant for potential overdose symptoms, and implement appropriate management strategies as needed.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that they should not use the product if they have a history of hypersensitivity to honey or benzoate preservatives without first consulting a healthcare professional.

Patients should be instructed to refrain from using the product if the solution changes color or becomes cloudy, or if the packaging is damaged. Serious conditions should be managed under the supervision of a healthcare provider, and patients should be made aware that they need to stop using the product and consult a doctor if they experience eye pain, changes in vision, or continued redness or irritation of the eye. Additionally, if the condition worsens, patients should also seek medical advice.

Before the first use, patients should check that the tamper ring is attached to the cap base, and they should remove the cap and discard the ring. To prevent contamination, patients must be reminded not to touch the tip of the container to any surface and to replace the cap after use. It is also essential to instruct patients to remove contact lenses before using the product and to wait at least 10 minutes before reinserting them. Patients should be informed that initial stinging and redness upon application of the drops is expected.

Storage and Handling

The product is supplied for single patient use only. It must be stored at temperatures below 25°C (77°F) to maintain its efficacy. After opening, the product should be discarded two months later to ensure safety and effectiveness.

Additional Clinical Information

Patients should instill 1 drop of the medication into the inner corner of the affected eye up to three times daily. Prior to the first use, it is essential to check that the tamper ring is attached to the cap base; the cap should be removed and the ring discarded. To prevent contamination, patients must avoid touching the tip of the container to any surface and should replace the cap after use. Contact lenses should be removed before application, and a minimum of 10 minutes should be allowed before reinserting them. Patients may experience initial stinging and redness upon application, which is expected.

Drug Information (PDF)

This file contains official product information for Optimel Manuka Dry Eye Drops, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)